Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
19 1월 2024 - 3:00AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an
upcoming presentation at CMR 2024 taking place online and in person
in London, UK from January 25-27, 2024.
Title: Effect of Aficamten on
Structure and Function in Patients with Obstructive Hypertrophic
Cardiomyopathy: The FOREST-HCM CMR
Sub-studyPresenter: Ahmad Masri, M.D., MS,
Director of the Hypertrophic Cardiomyopathy Center at Oregon Health
& Science UniversityDate: January 25,
2024Session Title: Rapid Fire – Large Clinical
Trials and RegistriesSession Time: 2:40 – 3:40 PM
GMTPresentation Time: 2:55 – 3:00 PM
GMTLocation: Kiosk 6R-TC-04, Cambridge
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory interactions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive topline results from
SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive
hypertrophic cardiomyopathy. Aficamten is also currently being
evaluated in two ongoing Phase 3 clinical trials: MAPLE-HCM,
evaluating aficamten as monotherapy compared to metoprolol as
monotherapy in patients with obstructive HCM and ACACIA-HCM,
evaluating aficamten in patients with non-obstructive HCM.
Cytokinetics is also developing omecamtiv mecarbil, a cardiac
muscle activator, in patients with heart failure. Additionally,
Cytokinetics is developing CK-136, a cardiac troponin activator for
the potential treatment HFrEF and other types of heart failure,
such as right ventricular failure, resulting from impaired cardiac
contractility, and CK-586, a cardiac myosin inhibitor with a
mechanism of action distinct from aficamten for the potential
treatment of HFpEF.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice
President, Corporate Communications, Investor Relations(415)
290-7757
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Cytokinetics (NASDAQ:CYTK)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024